TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22127619

Group type: EXPERIMENTAL
Intervention: PCL instructions
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: PCL + Graphic
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard prescription instructions (usual care)
Number of subjects: 94
Study: 20622409

Group type: EXPERIMENTAL
Intervention: Smokeless tobacco users
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Tobacco users
Number of subjects: 1200
Study: 18194120

Group type: EXPERIMENTAL
Intervention: Experimental group (steroid-free regimen): tacrolimus, mycophenolate mofetil, basiliximab induction, and steroids only for 3 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (steroid maintenance): tacrolimus, mycophenolate mofetil, basiliximab induction, and steroid maintenance
Number of subjects: 100
Study: 16055644

Group type: EXPERIMENTAL
Intervention: Self-affirmation before reading health-risk information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-affirmed group (control)
Number of subjects: 0
Study: 12133094

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTF) 2.5 ml (15‐20 microg.kg(‐1))
Number of subjects: 80

Group type: COMPARATOR
Intervention: Midazolam syrup (0.5 mg.kg(‐1))
Number of subjects: 80
Study: 10435771

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 30
Study: 7549900

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 2181941

Group type: EXPERIMENTAL
Intervention: Protocol I (5-FU 270-300 mg/m2 iv from day 1 to day 5 and ADM 25 mg/m2 iv on day 5)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Protocol II (5-FU, ADM plus CDDP 70 mg/m2 iv on day 1)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 77
Study: 7233072

Group type: EXPERIMENTAL
Intervention: 3:1 jejunoileal ratio
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: 1:3 jejunoileal ratio
Number of subjects: 265

Group type: COMPARATOR
Intervention: Unoperated patients
Number of subjects: 265
Study: 31831059

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28150508

Group type: EXPERIMENTAL
Intervention: CF guided PVAI
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional PVAI
Number of subjects: 50
Study: 26228714

Group type: EXPERIMENTAL
Intervention: Bench step exercise (3 times per day, 10-20 min each session, ≥140 min/week for 12 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study: 23588946

Group type: EXPERIMENTAL
Intervention: IV abatacept
Number of subjects: 3173
Study: 21423253

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation cycling (FESC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Passive cycling (PC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-cycling, electrically stimulated exercise (ES)
Number of subjects: 30
Study: 19517893

Group type: EXPERIMENTAL
Intervention: Test product (Omep-20)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 24
Study: 17672185

Group type: EXPERIMENTAL
Intervention: Continuous autotransfusion system (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 30
Study: 15145465

Group type: EXPERIMENTAL
Intervention: Nondeficit patients
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Deficit syndrome patients
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 61
Study: 11255587

Group type: EXPERIMENTAL
Intervention: Midwife-delivered brief smoking cessation intervention
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1120
Study: 9031450

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 150 anti‐Xa units per kg body weight, administered subcutaneously every 12 h for 7 days, initiated prior to streptokinase (SK)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 100 anti‐Xa units per kg body weight, administered subcutaneously after dose reduction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) 12,500 i.u. subcutaneously every 12 h for 7 days, initiated 4 h after start of SK infusion
Number of subjects: 100
Study: 8132379

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (50 mg/week)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (100 mg/week)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (sesame oil, 1 ml/week)
Number of subjects: 7
Study: 2948735

Group type: EXPERIMENTAL
Intervention: t‐PA (1.25 mg/kg iv over 3 hrs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Immediate PTCA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: t‐PA and PTCA
Number of subjects: 50

Group type: COMPARATOR
Intervention: t‐PA alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: t‐PA only
Number of subjects: 50
Study: 31672928

Group type: EXPERIMENTAL
Intervention: Velocity-Based Training (VBT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Percentage-Based Training (PBT)
Number of subjects: 27
Study: 28537849

Group type: EXPERIMENTAL
Intervention: 3-chamber bag
Number of subjects: 240

Group type: COMPARATOR
Intervention: Compounded monobag
Number of subjects: 240
Study: 26044962

Group type: EXPERIMENTAL
Intervention: Stent retrievers as device class
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical care alone
Number of subjects: 0
Study: 23570589

Group type: EXPERIMENTAL
Intervention: Deep hyperintensities (DHs) scores in PD-IC group (2.43 ± 2.79)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Deep hyperintensities (DHs) scores in PD-MCI group (4.48 ± 4.33)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Deep hyperintensities (DHs) scores in frontal areas for PD-IC (1.09 ± 1.31)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Deep hyperintensities (DHs) scores in frontal areas for PD-MCI (1.83 ± 1.90)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Deep hyperintensities (DHs) scores in parietal areas for PD-IC (0.09 ± 0.29)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Deep hyperintensities (DHs) scores in parietal areas for PD-MCI (0.65 ± 1.03)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Correlation of DHs with age
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Correlation of DHs with MMSE
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Correlation of DHs with verbal fluency test
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Correlation of DHs with orientation
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Correlation of DHs with executive function in CAMCOG-C
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis of MMSE scores
Number of subjects: 63
Study: 21605733

Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 355

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 355

Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 355
Study: 19699531

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg injection 1 week before surgery
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 68
Study: 16461054

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid (1.8 g ecosapentaenoic acid and 1.2 g docosahexaenoic acid)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 20
Study: 15266193

Group type: EXPERIMENTAL
Intervention: Lithium treatment (mean serum level 0.99 mEq/L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11785282

Group type: EXPERIMENTAL
Intervention: Blood pressure lowering, ACE inhibition, avoidance of nephrotoxins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timely involvement of specialized nephrology teams
Number of subjects: 0
Study: 9549917

Group type: EXPERIMENTAL
Intervention: Calcium alginate swabs
Number of subjects: 101

Group type: COMPARATOR
Intervention: Traditional cotton swabs
Number of subjects: 101
Study: 7834934

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3413270

Group type: EXPERIMENTAL
Intervention: Alcohol (0.85 g/kg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sober Type As
Number of subjects: 72
Study: 31688306

Group type: EXPERIMENTAL
Intervention: Herbal preparation (myrrh, chamomile flowers, coffee charcoal)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Mesalamine
Number of subjects: 38
Study: 29802953

Group type: EXPERIMENTAL
Intervention: Prolonged neuromuscular electrical stimulation (NMES) for 8 weeks, 40-min sessions, 5 days per week.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control period (no NMES).
Number of subjects: 14
Study: 28694151

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 109
Study: 26173606

Group type: EXPERIMENTAL
Intervention: Salpingotomy
Number of subjects: 446

Group type: COMPARATOR
Intervention: Salpingectomy
Number of subjects: 446
Study: 23644731

Group type: EXPERIMENTAL
Intervention: T3 sympathectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: T3-T4 sympathectomy
Number of subjects: 60
Study: 21732807

Group type: EXPERIMENTAL
Intervention: Aquatic exercise programme (14 weeks, 40 minutes per session, twice per week)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aquatic exercise programme
Number of subjects: 12
Study: 19211823

Group type: EXPERIMENTAL
Intervention: CR + vigorous-intensity exercise
Number of subjects: 112

Group type: COMPARATOR
Intervention: CR only
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: CR + moderate-intensity exercise
Number of subjects: 112

Group type: COMPARATOR
Intervention: CR only, CR + moderate-intensity exercise, CR + vigorous-intensity exercise
Number of subjects: 112
Study: 16913215

Group type: EXPERIMENTAL
Intervention: Actimel
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 14983492

Group type: EXPERIMENTAL
Intervention: Screening for prostate carcinoma with systematic sextant needle biopsy for men with elevated PSA levels and/or positive findings on digital rectal examination or transrectal ultrasound.
Number of subjects: 11210

Group type: EXPERIMENTAL
Intervention: Curative treatment offered to patients diagnosed with PAC.
Number of subjects: 11210

Group type: EXPERIMENTAL
Intervention: Screening protocol effectiveness.
Number of subjects: 11210
Study: 11282760

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 13
Study: 9203228

Group type: EXPERIMENTAL
Intervention: Idazoxan (100 micrograms/mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Idazoxan (200 micrograms/mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7951859

Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy (EIS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conservative medical treatment without EIS
Number of subjects: 65
Study: 3277876

Group type: EXPERIMENTAL
Intervention: Pethidine 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Meptazinol 75 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Self-administered intramuscular analgesia
Number of subjects: 10
Study: 29550891

Group type: EXPERIMENTAL
Intervention: mHealth intervention delivered by nurses
Number of subjects: 60
Study: 28723807

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 80
Study: 25619170

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23835546

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 21443301

Group type: EXPERIMENTAL
Intervention: Naltrexone with nicotine patch
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Co-occurring night smoking and sleep disturbance
Number of subjects: 385
Study: 18156649

Group type: EXPERIMENTAL
Intervention: One-cell biopsy (group I)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Two-cell biopsy (group II)
Number of subjects: 592
Study: 22329352

Group type: EXPERIMENTAL
Intervention: Consolidation thalidomide and prednisolone
Number of subjects: 0
Study: 16019280

Group type: EXPERIMENTAL
Intervention: Speed of processing training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social‐ and computer‐contact control group
Number of subjects: 0
Study: 14629244

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injections (25 units into each corrugator supercilii muscle, total 50 units)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injections
Number of subjects: 29
Study: 10454409

Group type: EXPERIMENTAL
Intervention: Bayesian methods in health technology assessment
Number of subjects: 0
Study: 8665991

Group type: EXPERIMENTAL
Intervention: FER 5 mg 9 mm tablets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FER 5 mg 11 mm tablets
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2213464

Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine 1:100,000
Number of subjects: 9

Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 9
Study: 351351

Group type: EXPERIMENTAL
Intervention: Influenza subunit vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serology tests or attempted isolation of virus
Number of subjects: 0
Study: 12222085

Group type: EXPERIMENTAL
Intervention: Various psychopharmacologic treatments (specific agents not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapies (specific agents not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel agents (specific agents not mentioned)
Number of subjects: 0
Study: 30896219

Group type: EXPERIMENTAL
Intervention: High patient-centered communication
Number of subjects: 231

Group type: COMPARATOR
Intervention: Low patient-centered communication
Number of subjects: 231
Study: 29358493

Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 26842957

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 84

Group type: COMPARATOR
Intervention: Older AEDs (carbamazepine or valproate sodium)
Number of subjects: 84
Study: 24698829

Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash (Group B)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Herbal mouthwash (Group A)
Number of subjects: 72
Study: 23265029

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.02 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Ketamine 100 microg/kg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 250
Study: 20306569

Group type: EXPERIMENTAL
Intervention: 0.5 mg kg(‐1) midazolam orally (group M)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.25 mg kg(‐1) midazolam orally with parental presence (group MP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Parental presence alone (group P)
Number of subjects: 60
Study: 19093049

Group type: EXPERIMENTAL
Intervention: QuiXfil (Xeno III; Dentsply DeTrey)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Tetric Ceram (Syntac Classic; Vivadent)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: QuiXfil
Number of subjects: 43

Group type: COMPARATOR
Intervention: Tetric Ceram
Number of subjects: 43
Study: 15813848

Group type: EXPERIMENTAL
Intervention: Epoetin-β 150 IU/kg three times weekly for 16 weeks
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 12508159

Group type: EXPERIMENTAL
Intervention: Baseline HIV-1 DNA level
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Baseline HIV-1 RNA level
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Infectious titer
Number of subjects: 111
Study: 11034875

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not treated with valproate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valproate (in three patients with traumatic epilepsy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stopping valproate administration
Number of subjects: 0
Study: 8674327

Group type: COMPARATOR
Intervention: Norepinephrine (pressor doses)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dopamine (3 micrograms/kg/min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Norepinephrine + Dopamine (3 micrograms/kg/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (control)
Number of subjects: 6
Study: 1511816

Group type: EXPERIMENTAL
Intervention: Dorsal duct stent placement (10 patients)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (9 patients)
Number of subjects: 19
Study: 6666689

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 60
Study: 30451760

Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral rectopexy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Stapled transanal rectal resection
Number of subjects: 112
Study: 29903762

Group type: EXPERIMENTAL
Intervention: eGVHD App
Number of subjects: 78

Group type: COMPARATOR
Intervention: No APP
Number of subjects: 78
Study: 26645673

Group type: EXPERIMENTAL
Intervention: Bench press training (TRA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 30
Study: 24479897

Group type: EXPERIMENTAL
Intervention: SILS (Single-Incision Laparoscopic Surgery)
Number of subjects: 42

Group type: COMPARATOR
Intervention: FPLC (Four-Port Laparoscopic Cholecystectomy)
Number of subjects: 42
Study: 21762279

Group type: EXPERIMENTAL
Intervention: Immuno-enhanced diet for 5 days before surgery (Group 1, n=14)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No enteral feeding products before surgery (Group 2, n=12)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No neoadjuvant therapy and no enteral feeding products before surgery (Group 3, n=13)
Number of subjects: 39
Study: 20472263

Group type: EXPERIMENTAL
Intervention: Silodosin (4 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18048463

Group type: EXPERIMENTAL
Intervention: OMT + PTA
Number of subjects: 56

Group type: COMPARATOR
Intervention: OMT
Number of subjects: 56
Study: 16234050

Group type: EXPERIMENTAL
Intervention: Cut/Coag output
Number of subjects: 267

Group type: COMPARATOR
Intervention: Pure-Cut output
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 267
Study: 11936554

Group type: EXPERIMENTAL
Intervention: Noncontingent reinforcement (NCR)
Number of subjects: 2
Study: 10022187

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Resin adhesive
Number of subjects: 40
Study: 7774212

Group type: EXPERIMENTAL
Intervention: Treatment group (DO2 > or = 600 mL/min/m2)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Patients who failed to achieve high DO2
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (DO2 450 to 550 mL/min/m2)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Overall myocardial infarction rate
Number of subjects: 89
Study: 2079568

Group type: EXPERIMENTAL
Intervention: alpha-Interferon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisone pretreatment
Number of subjects: 0
Study: 6775687

Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate eyedrops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Steroid therapy
Number of subjects: 0
Study: 30478888

Group type: EXPERIMENTAL
Intervention: Short Message Service (SMS)
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Structured Telephone Support (STS)
Number of subjects: 767

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: SMS
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: STS
Number of subjects: 767
Study: 29185929

Group type: EXPERIMENTAL
Intervention: Satiating diet (20-25% protein, 45-50% carbohydrate, 30-35% lipid; n=35)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control diet (10-15% protein, 55-60% carbohydrate, 30% lipid; n=34)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Satiating diet
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 69
Study: 28384627

Group type: EXPERIMENTAL
Intervention: Simultaneous group (27 patients) received oral and intratympanic steroid injections for 2 weeks.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sequential group (23 patients) treated with oral steroids for 2 weeks and intratympanic steroids for the subsequent 2 weeks.
Number of subjects: 50
Study: 25186259

Group type: EXPERIMENTAL
Intervention: SPACE FOR COPD (self-management intervention)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 184
Study: 21862399

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextrometorphane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18561865

Group type: EXPERIMENTAL
Intervention: Cod
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Salmon
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 324

Group type: COMPARATOR
Intervention: No seafood (control)
Number of subjects: 324